Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

ResearchDx

  • Home
  •  
  • ResearchDx



  • Most Read
  • Latest Comments
  • INOVIQ teams up with ResearchDx for improved cancer biomarker detection
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • INOVIQ teams up with ResearchDx for improved cancer biomarker detection
    • News

    AV uptake leads Audinate to push European expansion through recruiting drive
    Public
  • INOVIQ teams up with ResearchDx for improved cancer biomarker detection
    • Opinion

    What the SportsBet-BetEasy merger means for TabCorp and punters
    Public
  • INOVIQ teams up with ResearchDx for improved cancer biomarker detection
    • News

    Why this Tasmanian whisky brand had a record sales quarter
    Public
  • INOVIQ teams up with ResearchDx for improved cancer biomarker detection
    Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • INOVIQ validates exosome therapy to target and kill breast cancer cells
    INOVIQ validates exosome therapy to target and kill breast cancer cells
    • News

  • Genetic Signatures halts development of US respiratory product due to competition
    Genetic Signatures halts development of US respiratory product due to competition
    • News

  • Lumos completes phase 1 of developing premature birth detection test
    Lumos completes phase 1 of developing premature birth detection test
    • News

  • Genetic Technologies to pilot GeneType in US breast screening centres
    Genetic Technologies to pilot GeneType in US breast screening centres
    • News

  • Universal Biosensors receives FDA approval for its blood coagulation device
    Universal Biosensors receives FDA approval for its blood coagulation device
    • News

  • INOVIQ teams up with ResearchDx for improved cancer biomarker detection
    • News

    INOVIQ teams up with ResearchDx for improved cancer biomarker detection

    In 2023, the emerging cancer diagnostics market is estimated to be valued at over $23 billion. Everything is fair game in “finding a cure to cancer”—be it potentially using blood drops or narrowing in on exosomes, which are tiny structures our cells produce to transfer messages, proteins, lipids, the good stuff. These structures might also

    Read More
    Public
  • INOVIQ’s breast cancer test outperforms leading approved test, plans for further validation
    • News

    INOVIQ’s breast cancer test outperforms leading approved test, plans for further validation

    Precision diagnostics company INOVIQ (ASX: IIQ) has achieved noteworthy results from an independent clinical validation study of its SubB2M/CA15-3 test for breast cancer detection. The study has reported high accuracy (87%), sensitivity (81%), and specificity (93%) for the test, outperforming a leading approved CA15-3 test. INOVIQ CEO, Dr Leearne Hinch, said, “The outstanding results from

    Read More
    Public

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.